FDA Risk Management & REMS Assessment — GLPI-103

Uses the master safety specification from the EU-RMP (RMP-EU Part II). US risk management emphasizes labeling and the Medication Guide, consistent with the GLP-1 receptor agonist class.

Change History

1. Safety Concerns (per RMP-EU Part II)

Important identified risks: gastrointestinal adverse events; hypoglycaemia (with insulin secretagogues). Important potential risks: acute pancreatitis; thyroid C-cell tumours (MTC/MEN2); cardiovascular/heart-rate effects (APJ-mediated); immunogenicity. Missing information: pregnancy/lactation; paediatric use; severe renal/hepatic impairment; long-term and cardiovascular-outcomes safety.

2. REMS Necessity Assessment (FDAAA §505-1)

The determination of whether a REMS is required weighs: the seriousness of known/potential adverse events; the expected benefit; the duration of treatment; the seriousness of the disease; and the size of the treated population. Applying this framework:

• The identified and potential risks are consistent with the approved GLP-1 receptor agonist class and are well characterized.
• These risks have historically been manageable by routine, labeling-based risk management for approved GLP-1 products (which generally do not carry a REMS).
• The gastrointestinal and hypoglycaemia risks are manageable through titration and prescriber awareness; the potential risks (pancreatitis, thyroid C-cell) are addressed through contraindications, warnings, and the Medication Guide.

Conclusion: the benefits of routine risk management outweigh the incremental value of REMS elements; a REMS is not proposed. This determination will be re-evaluated if post-marketing data indicate a new or disproportionate risk not adequately mitigated by labeling.

3. Routine Risk Management — US Prescribing Information

• Boxed Warning — Thyroid C-cell tumours: consistent with the GLP-1 class; contraindication in patients with a personal or family history of MTC or MEN 2.
• Contraindications: personal/family history of MTC or MEN 2; prior serious hypersensitivity to GLPI-103.
• Warnings and Precautions: acute pancreatitis (discontinue if suspected); gastrointestinal adverse reactions (titrate; risk of dehydration/renal effects with severe events); hypoglycaemia with concomitant insulin/secretagogues (consider dose reduction of the secretagogue); cardiovascular/heart-rate monitoring (mechanism-related).
• Adverse Reactions: the most common were gastrointestinal; nausea 32.3% (IV) vs 21.4% (comparator), not significantly different (CSR-301 §12).
• Use in Specific Populations: pregnancy/lactation (limited data); renal/hepatic impairment (not studied in severe impairment); paediatric (not established).

4. Medication Guide (21 CFR 208)

A patient Medication Guide is dispensed, addressing: recognition of symptoms of thyroid tumours and acute pancreatitis; management of gastrointestinal effects through titration; and hypoglycaemia precautions when used with other glucose-lowering medicines.

5. Pharmacovigilance

Routine pharmacovigilance (FAERS signal detection; 15-day expedited and periodic safety reporting); targeted follow-up for pancreatitis and MTC; a pregnancy exposure registry; and a post-marketing long-term/cardiovascular safety study (aligned with the EU PASS, RMP-EU Part III).

6. Conclusion

GLPI-103's risks are adequately managed by routine, labeling-based risk minimization (including a class boxed warning and a Medication Guide) together with routine and post-marketing pharmacovigilance; no REMS is warranted at approval.